RxDoctor Payments Data

Min Cai, MD

Internal Medicine · Flushing, NYNPI 1003813676

Payments from drug & device makers

$3,881in general payments, 2019–2025

Across 197 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$481
  • Gilead$411
  • Johnson & Johnson$406
  • Amarin Pharma, Inc.$352
  • Sanofi-aventis U.S. LLC$340
  • plus $827 from 14 others

What the payments were for

  • Food & beverage$3,876100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,881 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$73,387
Medicare patients
109
Services billed
1,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl1,368$513,263
Diclofenac Epolamine725$495,165
CreonLipase/Protease/Amylase427$346,211
JardianceEmpagliflozin440$298,024
JanumetSitagliptin Phos/Metformin Hcl402$277,234
EliquisApixaban324$243,101
XareltoRivaroxaban359$240,500
JanuviaSitagliptin Phosphate332$222,670
RestasisCyclosporine308$190,808
LinzessLinaclotide247$130,004
Diclofenac Sodium331$124,612
Tresiba Flextouch U-200Insulin Degludec103$103,065
TrulicityDulaglutide91$98,973
FarxigaDapagliflozin Propanediol142$93,568
KerendiaFinerenone92$72,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Restasis, Linzess$1,064$667,023982 claims
MerckJanumet, Januvia$160$499,905734 claims
Boehringer IngelheimJardiance, Tradjenta$18$328,875495 claims
PfizerEliquis, Abrysvo$64$273,898431 claims
Johnson & JohnsonXarelto$406$240,500359 claims
Lilly USA, LLCTrulicity$153$98,97391 claims
AstraZenecaFarxiga$119$93,568142 claims
Novo NordiskRybelsus, Ozempic$481$90,49991 claims
GileadVemlidy$411$69,96247 claims
AmgenProlia$103$51,30431 claims
NovartisEntresto$17$31,74949 claims
Sanofi-aventis U.S. LLCMultaq$340$27,31824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →